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Inflammatory bowel diseases (IBDs), namely Crohn’s disease 
(CD) and ulcerative colitis (UC), affect nearly 2 million peo-
ple in the United States. Their etiologies remain elusive, as 
they involve complex interactions between genetic, environ-
mental, and immunoregulatory factors. UC is restricted to 
the colon and is a continuous superficial disease, involving 
predominantly the colonic mucosa, whereas CD can involve 
any segment of the gastrointestinal tract, with two-thirds of 
patients presenting with disease in the immunologically ac-
tive terminal ileum. For both UC and CD, current hypoth-
eses propose that damage to the intestinal mucosa occurs as 
a result of a dysregulated innate immune response triggered 
by microbial antigens (Fiocchi, 1998; Nagler-Anderson, 2001; 
Brazil et al., 2013). Thus, understanding the regulatory cir-
cuits that control aberrant innate immune responses in the 
intestine is critical to our understanding of IBD pathogenesis.
MicroRNAs (miRNAs) are emerging as critical gene 
regulators in a host of cellular processes, including inflam-
mation. They are endogenous, noncoding, single-stranded 
RNAs that are 20–23 nucleotides in length and exert regu-
latory functions through complementary base pairing to the 
3′ untranslated regions (UTRs) of protein-coding mRNAs. 
Currently, the role of miRNAs in mucosal immunity and 
IBD pathogenesis remains underexplored. However, recent 
investigations suggest that distinct miRNAs play a crucial role 
in the maintenance of immune homeostasis (O’Connell et 
al., 2010; Eulalio et al., 2012; Hsu et al., 2012). Chief among 
these, miR-223 is emerging as an important regulator of the 
innate immune system and the response to bacterial stimula-
MicrornA (mirnA)-mediated rnA interference regulates many immune processes, but how mirnA circuits orchestrate aber-
rant intestinal inflammation during inflammatory bowel disease (IBd) is poorly defined. Here, we report that mir-223 limits 
intestinal inflammation by constraining the nlrp3 inflammasome. mir-223 was increased in intestinal biopsies from patients 
with active IBd and in preclinical models of intestinal inflammation. mir-223-/y mice presented with exacerbated my-
eloid-driven experimental colitis with heightened clinical, histopathological, and cytokine readouts. Mechanistically, enhanced 
nLrP3 inflammasome expression with elevated IL-1β was a predominant feature during the initiation of colitis with mir-223 
deficiency. depletion of ccr2+ inflammatory monocytes and pharmacologic blockade of IL-1β or nLrP3 abrogated this phe-
notype. Generation of a novel mouse line, with deletion of the mir-223 binding site in the nLrP3 3′ untranslated region, 
phenocopied the characteristics of mir-223-/y mice. Finally, nanoparticle-mediated overexpression of mir-223 attenuated 
experimental colitis, nLrP3 levels, and IL-1β release. collectively, our data reveal a previously unappreciated role for mir-223 
in regulating the innate immune response during intestinal inflammation.
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tion (O’Connell et al., 2010; Dorhoi et al., 2013). miR-223 
was first identified and characterized in the hematopoietic 
system and shown to be specifically expressed in the myeloid 
compartment (Johnnidis et al., 2008). It is induced during 
myeloid differentiation and regulated by various transcription 
factors (Johnnidis et al., 2008). Moreover, miR-223 critically 
fine-tunes myeloid cell activity and plays various roles in in-
flammatory diseases by regulating multiple gene transcripts 
including granzyme B, the ubiquitin ligase Roquin, E2F1, 
NOD-like receptor activation, and the NF-κB pathway(Baek 
et al., 2008; Li et al., 2010; Pulikkan et al., 2010; Bauernfeind 
et al., 2012; Haneklaus et al., 2012, 2013). Recent data have 
revealed up-regulation of miR-223 as a novel biomarker in 
subsets of patients with IBD (Polytarchou et al., 2015) and in 
preclinical models of intestinal inflammation (Schaefer et al., 
2011; Zhou et al., 2015); nevertheless, there are limited mech-
anistic studies elucidating how miR-223–regulated gene cir-
cuits shape enteric inflammation.
The intracellular NOD-like receptor NLRP3 has 
emerged as a crucial regulator of intestinal homeostasis. It 
mediates the assembly of the inflammasome complex in re-
sponse to microbial ligands, triggering caspase-1 activation 
and secretion of cytokines IL-1β and IL-18, predominantly 
from myeloid and epithelial cells. Recent studies suggest that 
defective NLRP3 inflammasome signaling in the gut con-
tributes to IBD through increased epithelial permeability and 
detrimental immune responses against invading commensal 
bacteria (Allen et al., 2010; Zaki et al., 2010). Thus, under-
standing the molecular regulation of NLRP3 and its dysreg-
ulation during aberrant inflammation in IBD is an attractive 
avenue for therapeutic development. Although NLRP3 has 
been identified as an miR-223 target in vitro (Haneklaus et 
al., 2012), the role of miR-223 in the regulation of intestinal 
NLRP3 during IBD is unknown.
In this study, we identify miR-223 as a critical regu-
lator of the myeloid-specific NLRP3 inflammasome during 
intestinal inflammation. Mice genetically deficient in 
miR-223 display markedly exacerbated experimental colitis, 
as indicated by increased immune infiltration (neutrophils 
and monocytes), hyperactivated NLRP3, and IL-1β release. 
Generation of a mouse line with a deletion of the miR-223 
binding site in the NLRP3 3′ UTR phenocopies miR-223-/y 
mice, with exacerbated colitis and increased NLRP3 activity. 
Finally, nanoparticle delivery of miR-223 mimetics attenuates 
experimental colitis and restores the cytokine balance. Thus, 
we propose that miR-223 functions as a critical rheostat con-
trolling NLRP3 inflammasome activity and regulates the in-
flammatory tone of the intestine.
resuLts
Increased colonic mir-223 expression correlates with 
active inflammation during IBd and experimental dextran 
sodium sulfate (dss)–colitis
During intestinal inflammation such as occurs in IBD, there 
is a marked influx of various leukocyte populations into the 
inflamed intestine, which initiates tissue injury. Our under-
standing of how miRNA circuits regulate this innate immune 
sequelae is limited. We aimed to identify specific miRNAs 
that correlate with the inflammatory milieu and that hold 
promise as novel therapeutic targets. We identified miR-223 as 
a known myeloid-specific miRNA with significantly higher 
expression during active inflammation from mucosal biopsies 
of IBD patients (Fig. 1 A). In addition, whereas expression 
was negligible in the uninflamed mouse colon, administration 
of an epithelial irritant, DSS, dramatically induced expression 
of miR-223 (Fig. 1 B). Of note, this induction precedes his-
tological evidence of inflammation (day 2 after treatment) 
and is indicative of an early myeloid inflammatory influx 
(Fig. 1 C). To address whether the induction of miR-223 was 
a result of induced gene expression from tissue-resident leu-
kocytes compared with infiltrating immune cells, we depleted 
either neutrophils (anti-Ly6G) or monocytes (anti-CCR2) 
with antibodies during the onset of DSS treatment. Of note, 
neutrophil depletion significantly reduced miR-223 expres-
sion (35%), but monocyte depletion attenuated miR-223 
expression (67%) back to the level of uninflamed controls 
(Fig. 1 D). Thus, the initial source of miR-223 during acute 
colitis is from infiltrating neutrophils and monocytes. These 
data provided the rationale to assess the biological function of 
miR-223 during experimental colitis.
exacerbated dss-colitis in mir-223-/y mice
Based on the previous data showing increased miR-223 in 
IBD biopsies and preclinical models, we tested the hypothesis 
that increased miR-223 during active intestinal inflammation 
plays a functional role by performing a series of DSS-colitis 
experiments with miR-223-/y mice. Although miR-223-/y 
mice did not display any aberrant colonic inflammation at 
baseline, they exhibited markedly increased disease severity 
compared with WT counterparts during DSS-colitis as mea-
sured by weight loss and disease activity indices (Fig. 1, E and 
F). miR-223-/y mice presented with a significant increase in 
colonic ulceration and occult bleeding by day 3, at which 
time WT mice displayed only a mild histological inflamma-
tion and no gross ulceration (Fig.  1  G). Finally, enhanced 
colitis corresponded with a marked increase in all indices of 
colonic histopathology, including inflammatory infiltrates and 
overall tissue injury (Fig. 1, G–I).
 Recent work has demonstrated that certain mouse 
strains, in particular nlrp6−/− and IL-18−/− develop a dysbiotic 
microbiome and present with a transmissible, context-specific 
susceptibility to intestinal inflammation compared with co-
housed littermates (Elinav et al., 2011; Nowarski et al., 2015). 
To test whether the exacerbated colitis in miR-223-/y was 
transmissible or mediated by an intrinsic mechanism, we sub-
jected cohoused miR-223-/y and WT controls to DSS-colitis. 
As shown in Fig. S1 (A and B), whereas cohoused miR-223-/y 
mice displayed modestly variable weight loss and disease ac-
tivity index (DAI) during the course of colitis, there were 
no significant perturbations observed in the phenotype 
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compared with single-housed controls by day 6 after DSS 
treatment. This was evident by equivalent weight loss, occult 
bleeding, and diarrhea scores between single and cohoused 
counterparts. However, cohoused WT mice displayed in-
creased colonic shortening compared with single-housed lit-
termates, indicating a modest effect of cohoused miR-223-/y 
microbiome on some parameters of DSS-colitis (Fig. S1, A 
and B). Of note, the relative frequency of inflammatory in-
filtrates into the colon (specifically neutrophils and mono-
cytes) was unchanged between single or cohoused WT and 
miR-223-/y counterparts (unpublished data).
Hematopoietic deficiency of mir-223 enhances 
susceptibility to dss-colitis
Although our data depict a significant role for miR-223 in the 
control of intestinal inflammation, miR-223-/y mice, being a 
Figure 1. mir-223 regulates acute intestinal inflammation. (A) hsa-miR-223 expression was assessed in intestinal mucosal biopsies from patients 
with either CD or UC. n = 4–10 patients/group; statistical significance determined by ANO VA with Bonferroni’s multiple comparison test. (B) DSS (3% wt/
vol) was administered in drinking water ad libitum to B6.WT mice. Colonic mmu-miR-223 expression was determined from mice undergoing DSS-colitis 
(days 0, 2, 4, and 6). n = 3–5 mice/group; statistical significance determined by ANO VA with Newman–Keuls multiple comparison test. (C) Histopathology 
scores from DSS-colitis on days 0, 2, 4, and 6 of treatment (3% wt/vol). n = 5 mice/group; statistical significance determined by ANO VA with Newman–Keuls 
multiple comparison test. (D) Neutrophils were depleted with 300 µg (i.p.) anti-Ly6G (1A8) or isotype control on days 0 and 1 after DSS. Monocytes were 
depleted with 20 µg (i.p.) anti-CCR2 (MC21) or isotype control on days 0 and 1 after DSS. Mice were euthanized on day 2 after DSS, and miR-223 expression 
was analyzed in colon tissues. n = 5 mice/group; statistical significance determined by ANO VA with Newman–Keuls multiple comparison test. (E) Weight 
loss during DSS-colitis was expressed as the percentage of change from day 0. n = 9 mice/group; statistical significance determined by unpaired Student’s t 
test. (F) Clinical DAI was a composite of weight change (percentage of day 0), stool score, and occult blood index. n = 9 mice/group; statistical significance 
determined by unpaired Student’s t test. (G) Colon lengths of DSS-treated mice were assessed at the time of necropsy with representative macroscopic 
images. n = 9 mice/group; statistical significance determined by unpaired Student’s t test. (H) Histopathology scores from WT and miR-223-/y colons after 
DSS-colitis. n = 9 mice/group; statistical significance determined by unpaired Student’s t test. (I) Representative micrographs of colon H&E from WT and 
miR-223-/y mice 6 d after DSS-colitis. Data are expressed as mean ± SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus the indicated counterparts from 
three independent experiments. Bars, 100 µm.
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whole-body hemizygous knockout strain, do not definitively 
identify myeloid-derived miR-223 in this phenotype. To ad-
dress this, we generated BM chimeric animals as previously 
described (McNamee et al., 2011) to investigate the relative 
contribution of hematopoietic versus stromal/radio-resistant 
miR-233 in orchestrating intestinal inflammation. Our data 
identify hematopoietic-derived miR-223 (miR-223-/y → 
WT recipients) as driving exacerbated colitis, as indicated 
by increased DAI, weight loss, colon shortening, and histo-
logical indices compared with controls (WT → miR-223-/y 
recipients; Fig. 2, A–D). miR-223 has maximal expression in 
BM-derived egressing neutrophils and monocytes, which are 
not yet matured within tissues (Johnnidis et al., 2008; Bau-
ernfeind et al., 2012; Haneklaus et al., 2012). Thus, our data 
suggest that the increase in colonic miR-223 in patients with 
active IBD and experimental DSS-colitis is derived from in-
filtrating myeloid cells.
Increased myeloid infiltrate and IL-1β expression in 
mir-223-/y mice during the onset of dss-colitis
To further dissect the hematopoietic-derived cellular pop-
ulations driving exacerbated DSS-colitis in miR-223-/y 
mice, we assessed the cellular infiltrate at the early phase of 
DSS-colitis (day 0–2). Increased histological inflammation 
and tissue damage in miR-223-/y mice was accompanied by 
an enhanced colonic influx of both neutrophils and mono-
cytes, although tissue macrophage frequencies appeared nor-
mal (Fig. 3, A–D). Similar to previous publications, a modest 
decrease in CD11c+ dendritic cells was also observed (Zhou 
et al., 2015; Fig. 3 E). To further investigate a causative mech-
anism for exacerbated DSS-colitis in miR-223-/y mice, we 
assessed cytokine expression patterns during early disease (day 
2). Surprisingly, an increase in expression of IL-1β compared 
with WT counterparts was the predominant cytokine pheno-
type from the colons of miR-223-/y mice (Fig. 3 F). Finally, 
we investigated the expression of neutrophil and monocyte 
chemokines and demonstrated that the IL-1β–inducible 
chemokines CXCL1, CXCL2, and CCL2 (Calkins et al., 
2002) were significantly induced in miR-223-/y colons and 
correspond with the enhanced influx of both neutrophils and 
monocytes (Fig. 3. G–I).
Increased nLrP3 inflammasome activity in mir-223-/y 
mice during dss-colitis
Based on the finding that myeloid-derived miR-223 regu-
lates intestinal inflammation and that a predominant pheno-
type of the early colitic response was enhanced IL-1β release, 
we next investigated a role for the miR-223 target mRNA, 
NLRP3. The NLRP3 protein was identified as a bona fide 
miR-223 target (Bauernfeind et al., 2012; Haneklaus et 
al., 2012; Fig. 4 A) that is conserved across species and has 
been shown to be critical for intestinal homeostasis and the 
sensing of bacterial ligands (Zaki et al., 2010, 2011). To de-
fine a functional effect of miR-223 deficiency on NLRP3 
inflammasome function, we observed an increase in IL-1β 
protein in colons from miR-223-/y mice compared with 
WT counterparts, both at baseline and after established 
DSS-colitis (Fig.  4  B). Next we assessed the relative ex-
Figure 2. Hematopoietic-derived mir-223 con-
strains experimental dss-colitis. BM chimeric mice 
were generated after irradiation of WT (CD45.1) or 
miR-223-/y (CD45.2) mice. 8 wk after irradiation, DSS 
was administered in drinking water ad libitum (3% wt/
vol) for 6 d. (A) Clinical DAI was a composite of weight 
changes (percentage of day 0), stool score, and occult 
blood index. n = 5–10 mice/group; statistical signif-
icance determined by ANO VA with Newman–Keuls 
multiple comparison test. (B) Colon lengths were 
assessed at the time of necropsy, and representative 
macroscopic images were acquired. n = 5 mice/group; 
statistical significance determined by ANO VA with 
Newman–Keuls multiple comparison test. (C) Histopa-
thology scores from WT and miR-223-/y colons. n = 
5–10 mice/group; statistical significance determined 
by ANO VA with Newman–Keuls multiple comparison 
test. (D) Representative micrographs of colon H&E 
from WT and miR-223-/y mice 6 d after DSS-colitis. 
Data are expressed as mean ± SEM; *, P < 0.05; 
**, P < 0.01; ***, P < 0.001 versus WT counterpart from 
two independent experiments. Bars, 100 µm.
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pression of NLRP3 protein in whole colonic lysates from 
mice with DSS-colitis. miR-223-/y mice exhibited increased 
expression of NLRP3 protein (or increased numbers of 
NLRP3-expressing cells) and secreted IL-1β compared with 
WT counterparts (Fig. 4 C). Next, we stimulated BMDMs 
from WT or miR-223-/y mice to prime the formation of 
the inflammasome (LPS treatment) and assessed the secre-
tion of IL-1β protein (after activation with ATP). Activated 
BMDM from miR-223-/y mice exhibited increased expres-
sion of NLRP3 protein and mature IL-1β compared with 
WT cells (Fig. 4 D). Interestingly, although miR-223 defi-
ciency did not affect the mRNA expression of IL-1β, IL-18, 
or TNF (Fig. 4, E–G), miR-223-/y BMDM secreted higher 
levels of mature IL-1β and IL-18 protein compared with WT 
cells, without altering TNF (Fig. 4, H–J). These data confirm 
a selective and functional role for miR-223 in regulating a 
critical component of myeloid cell activation in the intestine, 
the NLRP3 inflammasome.
Antibody depletion of ccr2+ inflammatory 
monocytes dampens IL-1β expression and 
dss-colitis in mir-223-/y mice
Based on our observation that monocyte depletion inhib-
its the expression of miR-223 (Fig.  1  D) and the finding 
that miR-223-/y mice present with increased monocytes and 
neutrophils during DSS-colitis, we investigated the impact of 
either monocyte or neutrophil depletion during colitis. Flow 
cytometry confirmed a selective depletion of either mono-
cytes (anti-CCR2; MC21) or neutrophils (anti-Ly6G, 1A8; 
Fig. 5, A and B) after treatment. Neutrophil depletion was fur-
ther confirmed by depletion for iNOS mRNA (Fig. 5 J) but 
appeared to have no effect on intestinal inflammation. How-
ever, anti-CCR2 depletion of inflammatory monocytes abro-
gated histological indices of colitis and tissue damage (Fig. 5, 
C and D). Consistent with a previous study (Seo et al., 2015), 
CCR2+ monocyte depletion further depleted colonic IL-1β 
levels in miR-223-/y mice (Fig. 5 E). We demonstrated that 
IL-1β mRNA is repressed after CCR2 treatment (Fig. 5 F), 
as are the transcripts for the IL-1β–induced genes IL-6 and 
CXCL1. Importantly, expression of TNF mRNA was com-
parable in both anti-Ly6G and anti-CCR2 groups, indicating 
a selective role for monocyte-derived IL-1β in driving en-
hanced colitis pathology in miR-223-/y mice (Fig. 5, G–I).
Blockade of the nLrP3 inflammasome or IL-1β 
abrogates the enhanced pathology of mir-223-/y 
mice during dss-colitis
Next we investigated whether selective pharmacologic 
blockade of either the NLRP3 inflammasome or IL-1β 
would directly further limit colitis in miR-223-/y mice. 
Figure 3. onset of colitis in mir-223-/y mice is characterized by the enhanced expression of IL-1β and influx of neutrophils and monocytes. 
DSS was administered in drinking water ad libitum (3% wt/vol) to WT and miR-223-/y mice for 2 d. (A–D) Flow cytometry characterized collagenase digested 
colons for the presence of live, CD45+ CD11b+ myeloid cells that were neutrophils (Ly6G+ MHC II−; A), monocytes (Ly6C+ MHC II−; B), intermediate monocytes 
(Ly6C+ MHC II+; C), macrophages (Ly6C− MHC II+; D), and dendritic cells (MHC II+ CD11c+ CD11b−; E). n = 4 mice/group; statistical significance determined by 
two-way ANO VA with Bonferroni test. (F) Inflammatory cytokine expression was quantified in whole colon tissues from WT or miR-223-/y mice after DSS 
by LEG ENDplex bead array (see Materials and methods) or ELI SA (IL-18). n = 4 mice/group; statistical significance determined by unpaired Student’s t test. 
(G–I) Relative gene expression of the neutrophil and monocyte chemokines CXCL1 (G), CXCL2 (H), and CCL2 (I) was measured by RT-PCR from whole colon 
tissue and expressed relative to 18s. n = 5 mice/group; statistical significance determined by ANO VA with Newman–Keuls multiple comparison test. Data 
are expressed as mean ± SEM; *, P < 0.05; **, P < 0.01 versus the indicated counterpart from two independent experiments.
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Therefore, miR-223-/y mice were treated with either the 
NLRP3 inhibitor MCC950 or the IL-1 receptor antagonist 
anakinra for the duration of DSS-colitis. As shown in Fig. 6, 
A–D, both treatment regimens significantly attenuated the 
clinical signs of colitis, including weight loss, DAI, and colon 
length. Histopathologic indices were further repressed by 
both MCC950 and anakinra administration (Fig.  6, E and 
F). We also observed that colonic monocyte and neutro-
phil frequencies were reduced to those of WT mice treated 
with DSS (Fig.  6, G and H). Last, although inflammatory 
cytokines TNF and IL-6 were unaltered, colonic IL-1β 
was significantly lower after treatment (Fig.  6, I–K). Thus, 
heightened NLRP3 activation with subsequent increased 
mature IL-1β accounts for the enhanced experimental coli-
tis in miR-223-/y mice.
Generation of mir-223 target site knockout 
mice (nlrp3m223del) and assessment of nLrP3 
function in vitro and in vivo
Our in vitro experiments implicated miR-223 as a critical 
negative regulator of NLRP3 expression. To test the 
importance of this interaction in vivo, we generated a mouse 
with the possibility to conditionally knock out 92 bp of the 
NLRP3 3′ UTR, including the miR-223 target site, using the 
CMV-Cre-Lox system. Compared with the available models 
that interfere with miR-223, namely hemizygous knockout 
miR-223-/y mice (Johnnidis et al., 2008) or mice transplanted 
with BM expressing an miR-223 “sponge” (Gentner et al., 
2009), our approach does not alter the ability of miR-223 
to regulate all other targets. There is the possibility that this 
deletion in the NLRP3 3′ UTR affects folding of the region, 
Figure 4. Increased nLrP3 inflamma-
some activity in BMdMs and colons 
from mir-223-/y mice during dss-colitis. 
(A) Schematic of in silico miR-223 binding 
sequence to the 3′ UTR of the mouse NLRP3 
and conservation across multiple species. (B) 
ELI SA measurement of IL-1β in whole colon 
biopsies from WT and miR-233-/y mice on day 
6 after DSS-colitis. n = 5 mice/group; statis-
tical significance determined by ANO VA with 
Newman–Keuls multiple comparison test. (C) 
Western immunoblot assessment of NLRP3, 
pro–IL-1β, cleaved IL-1β, ASC, and β-actin in 
whole colon biopsies from WT and miR-233-/y 
mice on day 6 after DSS-colitis. Representa-
tive immunoblot from three independent mice. 
(D) Western immunoblot assessment of 
NLRP3, IL-1β, and β-actin in BMDM after 6-h 
treatment with media vehicle or LPS (100 ng/
ml). Representative immunoblot from three 
independent mice. (E–J) BMDMs were cultured 
for 5 d and primed with LPS (100 ng/ml) for 
3 h, and NLRP3 was activated with ATP (1 mM) 
for 3 h. Gene expression of IL-1β (E), IL-18 (F), 
and TNF (G) were assessed by quantitative PCR. 
n = 3–4 mice/group; statistical significance 
determined by two-way ANO VA with Bonfer-
roni test. Secreted cytokines IL-1β (H), IL-18 
(I), and TNF (J), were quantified in cell-free 
supernatants by ELI SA. n = 3–4 mice/group; 
statistical significance determined by two-way 
ANO VA with Bonferroni test. Data are ex-
pressed as mean ± SEM; *, P < 0.05; **, P < 
0.001 versus the indicated counterpart from 
two independent experiments.
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however no structural motifs are found in this area by the 
algorithm RegRNA (http ://regrna2 .mbc .nctu .edu .tw /) 
except for a GY-box that is actually within the miR-223 
binding site (Huang et al., 2006). Thus removal of NLRP3 
inhibition by miR-223 is likely to be the dominant functional 
effect in this strain of mice. These mice were then crossed 
with CMV-Cre mice to globally knock out the miR-223 
target site (Nlrp3m223del; Fig. S2). To determine the absolute 
regulation of NLRP3 by miR-223, we analyzed NLRP3 
expression and NLRP3 inflammasome activity in neutrophils 
Figure 5. depletion of ccr2+ monocytes attenuates dss-colitis and IL-1β in mir-223-/y mice. DSS was administered in drinking water ad libitum 
(3% wt/vol) for 6 d to miR-223-/y mice. Mice were treated on days 0–5 with anti-Ly6G (1A8; 300 µg/d, i.p.), anti-CCR2 (MC21; 20 µg/d, i.p.), or isotype ve-
hicles and euthanized 24 h after the final treatment. (A) Representative flow cytometry analysis from miR-223-/y mice subjected to DSS (3% wt/vol; day 2). 
(B) Neutrophils were identified as live, CD45+ singlets, SSC-Ahigh GR1high CD11b+; monocytes were identified as live, CD45+ singlets, SSC-Ahigh GR1int CD11b+. 
n = 3 mice/group; statistical significance determined by ANO VA with Newman–Keuls multiple comparison test. (C) Histopathology scores from miR-223-/y 
mice after DSS-colitis. n = 5 mice/group; statistical significance determined by ANO VA with Newman–Keuls multiple comparison test. (D) Representative 
micrographs of colon H&E from miR-223-/y mice after DSS-colitis. (E) IL-1β was measured by ELI SA from whole colon tissue. n = 5 mice/group; statistical 
significance determined by ANO VA with Newman–Keuls multiple comparison test. (F–J) mRNA for IL-1β (F), TNF (G), IL-6 (H), CXCL1 (I), and iNOS (J) was as-
sessed by QPCR from whole colon tissue. n = 4–5 mice/group; statistical significance determined by ANO VA with Newman–Keuls multiple comparison test. 
Data are expressed as mean ± SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus the indicated counterpart from two independent experiments. Bars, 100 µm.
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Figure 6. Inhibition of nLrP3 or IL-1β attenuates dss-colitis in mir-223-/y mice. DSS was administered in drinking water ad libitum (3% wt/vol) 
for 6 d to WT and miR-223-/y mice. miR-223-/y mice received the small molecule inhibitor of NLRP3, MCC950 (20 mg/kg/d, i.p.); the IL-1 receptor antago-
nist, anakinra (20 mg/kg/d, i.p.); or saline vehicle and were euthanized 24 h after the final treatment. (A) Weight loss during colitis was expressed as the 
percentage of change from day 0. n = 7–9 mice/group; statistical significance determined by ANO VA with Newman–Keuls multiple comparison test. (B) 
Clinical DAI was a composite of weight changes (percentage of day 0), stool score, and occult blood index. n = 7–9 mice/group; statistical significance 
determined by ANO VA with Newman–Keuls multiple comparison test. (C) Colon lengths of DSS-treated mice were assessed at the time of necropsy. n = 6–9 
mice/group; statistical significance determined by ANO VA with Newman–Keuls multiple comparison test. (D) Representative macroscopic images of colons 
after treatment. (E) Histopathology scores from WT and miR-223-/y colons after DSS-colitis. n = 6–9 mice/group; statistical significance determined by 
ANO VA with Newman–Keuls multiple comparison test. (F) Representative micrographs of colon H&E from WT and miR-223-/y mice after treatment. (G and 
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from Nlrp3m223del mice stimulated with LPS and nigericin to 
activate the NLRP3 inflammasome. A consistent increase in 
NLRP3 expression was observed in resting and LPS-stimulated 
knockout neutrophils (del/del) compared with WT (+/+; 
Fig. 7 A). Compared with WT controls, there was a marked 
increase in the production of mature IL-1β in homozygous 
knockout neutrophils (Fig. 7 B) with no significant difference 
in TNF (Fig. 7 C). Furthermore, although miR-223 mimics 
transfected into WT (+/+) monocytes repressed NLRP3, 
Nlrp3m223del (del/del) monocytes were refractory to this 
treatment (Fig. S3). Collectively, these data confirm that we 
have generated mice in which NLRP3 is no longer inhibited 
by myeloid-derived miR-223.
We next tested the functional consequence on experi-
mental colitis in vivo. We found that Nlrp3m223del mice were 
more susceptible to DSS-colitis, as indicated by an increase in 
infiltrating neutrophils in addition to increased weight loss, re-
duced colon length, and higher histology score (Fig. 7, D–H). 
Thus, our collective data underscore that in vivo, NLRP3 is 
the bone fide target of miR-223, and that this is a critical 
determinant of intestinal inflammation.
nanoparticle delivery of an mir-223 mimetic attenuates 
experimental dss-colitis
Small molecules targeting the pathways involved in aber-
rant inflammation are the focus of intense investigation for 
the treatment of IBD. Currently, although the first-in-class 
miRNA oligonucleotide therapeutic (Miravirsen) demon-
strates efficacy in clinical trials for hepatitis C (Janssen et al., 
2013), there is no therapeutic application of miRNAs for 
IBD. Based on our data, we sought to investigate the efficacy 
of using miR-223 mimetics as a novel therapeutic interven-
tion during experimental colitis. Synthetic murine miR-223 
mimics were delivered to mice in nanoparticle lipid emulsion 
(i.v.; on days 1 and 3 after DSS administration). As a rele-
vant control, we used a corresponding miRNA control that 
is restrictively expressed in Caenorhabditis elegans nematode 
(Cel-miR-239b). As shown in Fig. 8 A, therapeutic interven-
tion with synthetic miR-223 mimics produced a threefold 
increase in colonic miR-223 expression during peak disease 
(day 6 after DSS). This was accompanied by a marked pro-
tection from DSS-colitis as indicated by attenuated occult 
bleeding, weight loss, and edema (Fig. 8, B–E). Furthermore, 
mmu-miR-223 mimic treatment repressed the miR-223 tar-
get, NLRP3, at both mRNA and protein levels (Fig. 8, F and 
G). This was accompanied by attenuated IL-1β protein and 
repression of IL-1β, IL-6, TNF, and CXCL1 mRNA tran-
scripts (Fig.  8, H and I). Collectively, these data confirm a 
critical role for miR-223 during aberrant intestinal inflam-
mation and represent a proof-of-principle therapeutic study 
using miRNA mimetics to treat experimental IBD.
dIscussIon
The resident and infiltrating subsets of myeloid cells that 
populate the intestine play dual roles in intestinal immunity, 
with the capacity to protect from commensal overstimulation 
while acting as provocateurs in immune-mediated conditions 
such as IBD. Although the etiology of IBD remains elusive 
(with genetic, environmental, and immune components), 
prevailing hypotheses propose that damage to the intestinal 
mucosa occurs as a result of a dysregulated innate immune 
response triggered by microbial antigens (Fiocchi, 1998; 
Nagler-Anderson, 2001). The NOD-like receptor family, 
pyrin domain-containing protein 3 (NLRP3) inflammasome 
is critical for the processing and release of active IL-1β and 
IL-18 and is rapidly emerging as a crucial regulator of intestinal 
homeostasis (Zaki et al., 2011; Haneklaus et al., 2013). Thus, 
understanding the molecular regulation of the inflammasome 
complex and its dysregulation during aberrant inflammation 
in IBD is an attractive avenue for therapeutic development.
Because of the ability of IL-1β and IL-18 to drive robust 
proinflammatory responses, they are tightly regulated at mul-
tiple levels to avoid excessive tissue damage. However, the role 
of the NLRP3 inflammasome in acute intestinal inflamma-
tion is controversial, with multiple conflicting studies identi-
fying opposing functions during experimental colitis. A series 
of studies demonstrated that mice deficient in inflammasome 
components, NLRP3, caspase-1, or apoptosis-associated 
speck-like protein containing a CARD (ASC), have height-
ened susceptibility to DSS-colitis (Allen et al., 2010; Zaki et 
al., 2010; Song-Zhao et al., 2014). Conversely, another study 
revealed protective responses in Nlrp3−/− mice using the same 
model (Bauer et al., 2010), whereas pharmacologic inhibi-
tion of either caspase-1 or inflammasome activation damp-
ened chronic colitis in IL-10−/− mice (Zhang et al., 2014). 
Although some of these discrepancies across multiple studies 
may be explained by experimental design and microbiome 
differences, they highlight a need to further define the mo-
lecular regulation of aberrant cytokine stimulation in the in-
testine. One possible explanation lies in the respective roles 
of IL-1β versus IL-18 to drive both inflammation and repair 
(Bamias et al., 2012; Lopetuso et al., 2013).
Indeed, a role for the proinflammatory cytokine IL-1β 
in the pathogenesis of IBD has been controversial. Increased 
levels of IL-1β were found in colonic biopsies and isolated 
myeloid cells, correlating with disease severity (Ligumsky et 
H) Flow cytometry–characterized collagenase digested colons for the presence of live, CD45+ CD11b+ myeloid cells that were neutrophils (Ly6G+ MHC II-; G) 
and monocytes (Ly6C+ MHC II-; H). n = 3–5 mice/group; statistical significance determined by ANO VA with Newman–Keuls multiple comparison test. (I–K) 
Inflammatory cytokine expression was quantified in whole colon tissues from WT or miR-223-/y mice after treatment by LEG ENDplex bead array (see Mate-
rials and methods). n = 5–7 mice/group; statistical significance determined by ANO VA with Newman–Keuls multiple comparison test. Data are expressed as 
mean ± SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus the indicated counterparts from two independent experiments. Bars, 100 µm.
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al., 1990; Reinecker et al., 1993; Casini-Raggi et al., 1995). 
Although early studies demonstrated that low-dose recom-
binant IL-1β protected from the induction of experimental 
colitis (Cominelli et al., 1990), more recent data have estab-
lished that inflammatory monocytes and monocyte-derived 
IL-1β play a major role in driving pathology in DSS-colitis 
(Seo et al., 2015). This is exemplified by protection from acute 
DSS-colitis in IL-1β−/− and CCR2−/− mice or by antibody 
depletion of CCR2+ monocytes (Andres et al., 2000; Zig-
mond et al., 2012; Seo et al., 2015). In support of these find-
ings, Shouval et al. (2016) reported a marked improvement in 
two IL-10R−/− patients with severe and treatment-refractory 
infant-onset IBD after treatment with IL-1ra (anakinra).
Likewise, with respect to IL-18, recent landmark studies 
have demonstrated that nonhematopoietic IL-18 plays a re-
parative role after epithelial damage during DSS-colitis. Both 
Figure 7. nlrp3m223del mice display increased nLrP3 activation in vitro and susceptibility to dss-colitis. (A) Neutrophils were cultured ex vivo from 
WT (+/+) or Nlrp3m223del (del/del) mice and stimulated with LPS (1 or 100 ng/ml) for 3 h, as indicated. Samples were lysed in SDS loading buffer and NLRP3, 
and β-actin protein expression was analyzed by Western immunoblot. Representative immunoblot from three independent mice. (B and C) Neutrophils 
were cultured with LPS (100 ng/ml) for 3 h, followed by 3 h with nigericin (10 mM), and supernatants were collected for IL-1β (B) or TNF (C) measurement 
by ELI SA. n = 4 mice/group; statistical significance determined by unpaired Student’s t test. DSS was administered in drinking water ad libitum (3% wt/
vol) for 6 d to WT and Nlrp3m223del mice. (D) Weight loss during colitis was expressed as the percentage of change from day 0. n = 3 mice/group; statistical 
significance determined by unpaired Student’s t test. (E) Colon lengths were assessed at the time of necropsy from WT and Nlrp3m223del mice after DSS. n = 3 
mice/group; statistical significance determined by unpaired Student’s t test. (F) Histopathology scores from WT and Nlrp3m223del colons after DSS. n = 3 mice/
group; statistical significance determined by unpaired Student’s t test. (G) Representative micrographs of colon H&E from WT and Nlrp3m223del mice after 
DSS-colitis. (H) The frequencies of monocytes, macrophages, and neutrophils were analyzed in WT and Nlrp3m223del mice by flow cytometry as a percentage 
of myeloid cells (gated on CD45+ CD11b+ cells) in the colon at day 2 after DSS treatment. n = 3 mice/group; statistical significance determined by unpaired 
Student’s t test. Data are expressed as mean ± SEM; *, P < 0.05; **, P < 0.01 versus the indicated counterparts. Data are representative of two independent 
experiments with three to four mice per group. Bars, 1 mm.
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nlrp3−/− and casp1−/− mice present with enhanced suscepti-
bility to colitis, and treatment of casp1−/− mice with recombi-
nant IL-18 can rescue this pathology (Zaki et al., 2010, 2011). 
In contrast, inhibition of IL-18 has been shown to confer 
protection in experimental colitis, supporting a procolito-
genic role for IL-18. This is elegantly illustrated by protection 
from DSS-colitis in mice with selective deletion of IL-18 or 
its receptor IL-18R1 in intestinal epithelial cells (Nowarski et 
al., 2015). Conversely, deletion of the IL-18 negative regula-
tor, IL-18bp, resulted in severe colitis associated with loss of 
goblet cells (Nowarski et al., 2015).
It is worth noting that a confounding factor to the in-
terpretations of these discrepant studies lies in the effects of 
IL-18 on the microbiome, where an outgrowth of pathogenic 
Figure 8. nanoparticle delivery of an mir-223 mimetic attenuates experimental dss-colitis. DSS was administered in drinking water ad libitum 
(3% wt/vol) for 6 d to WT mice. Mice were treated with 50 µg (via retro-orbital injection) of either control (Cel-miR239b) or miR-223 mimetic in a nanopar-
ticle solution on days 1 and 3 after DSS administration. (A) miR-223 expression was measured in whole colon tissue by QPCR on day 4 after DSS. (B) Weight 
loss during treatment was expressed as the percentage of change from day 0. n = 9 mice/group; statistical significance determined by unpaired Student’s 
t test. (C) Clinical DAI was a composite of weight changes (percentage of day 0), stool score, and bleeding index. n = 9 mice/group; statistical significance 
determined by unpaired Student’s t test. (D) Colonic histopathology scores after treatment. n = 9 mice/group; statistical significance determined by unpaired 
Student’s t test. (E) Representative micrographs of colon H&E from treated mice after DSS-colitis. (F) Western immunoblot assessment of NLRP3, ASC, and 
β-actin in whole colon biopsies. Representative immunoblots from three independent mice. (G) Relative mRNA was assessed by quantitative PCR for NLRP3. 
n = 3–5 mice/group; statistical significance determined by unpaired Student’s t test. (H) ELI SA measurement of IL-1β whole colon biopsies. n = 3–5 mice/
group; statistical significance determined by unpaired Student’s t test. (I) Relative mRNA was assessed by QPCR for IL-1, TNF, IL-6, and CXCL1 in whole colon 
tissues. n = 3–5 mice/group; statistical significance determined by unpaired Student’s t test. Data are expressed as mean ± SEM; *, P < 0.05; **, P < 0.01 
versus the indicated counterpart from two independent experiments. Bars, 100 µm.
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intestinal microbial communities is observed in IL-18−/− 
mice (Elinav et al., 2011; Henao-Mejia et al., 2012). Fur-
thermore, although DSS-colitis represents a model of acute 
injury that is self-limiting, varied courses of DSS administra-
tion and concentrations (∼2–6% wt/vol) will invariably con-
found the extrapolation of this work to the clinical setting. 
DSS-induced epithelial cell death releases alarmins such as 
IL-1α that initiate and exacerbate the inflammatory response 
(Bersudsky et al., 2014). As such, heightened epithelial cell 
death or chronic periods of active inflammation, without al-
lowing for reparative signaling in the mucosa, will present 
with altered cytokine kinetics compared with acute and lim-
ited insults. We observed no role for miR-223 in nonhema-
topoietic cells (Fig. 2) and the levels of IL-1α and IL-18 were 
comparable in WT and miR-223-/y mice after the initiation 
of acute DSS-colitis (Fig.  3). As such, our data using three 
different model systems of miR-223 deficiency (miR-223-/y, 
miR-223-/y chimeras, and Nlrp3m223del) suggest that the in-
flux of myeloid cells with heightened and prolonged release 
of mature IL-1β may override any protective effect of IL-18 
on the epithelium. This role for excessive myeloid-driven in-
flammation is supported by protection from acute DSS-colitis 
in IL-1β−/− and CCR2−/− mice or by antibody depletion 
of CCR2+ monocytes (Andres et al., 2000; Zigmond et al., 
2012; Seo et al., 2015). In addition, we provide data that selec-
tive pharmacologic blockade of NLRP3 (MCC950), IL-1β 
inhibition (anakinra), or nanoparticle delivery of miR-223 
mimetics exhibit a marked and protective effect during the 
course of acute colitis.
Within the myeloid lineage, miR-223 is lowest in ma-
ture, tissue-resident macrophages but higher in circulating 
monocytes and neutrophils (Johnnidis et al., 2008; Bauern-
feind et al., 2012; Haneklaus et al., 2012). Although our data 
and the current literature indicate a proinflammatory role for 
monocytes infiltrating the inflamed colon during DSS-colitis, 
NLRP3 is expressed in several other myeloid-derived cells, 
and thus miR-223–NLRP3 interactions may have cell and 
tissue intrinsic effects in different disease states or infections. 
The miR-223–NLRP3 interaction is particularly important 
in neutrophils. For example, miR-223 expression is highest in 
human and mouse neutrophils compared with macrophages 
(Ramkissoon et al., 2006; Johnnidis et al., 2008), and neutro-
phils have a functional NLRP3 inflammasome (Mankan et 
al., 2012; Karmakar et al., 2015). The enhanced secretion of 
IL-1β with miR-223 deficiency may also drive IL-1β–medi-
ated expression of chemokines CXCL1, CXCL2, and CCL2 
from a multitude of cellular sources and plays a direct role in 
the recruitment of neutrophils and monocytes into inflamed 
tissues (Calkins et al., 2002), thus agreeing with our observa-
tion of increased neutrophils and monocytes in the inflamed 
colons of miR-223–deficient mice or Nlrp3m223del mice in 
which NLRP3 is no longer regulated by miR-223. In addi-
tion, a direct role for miR-223 on CXCL2 has been observed 
in the setting of tuberculosis, and this may have an additive role 
during DSS-colitis in miR-223-/y mice (Dorhoi et al., 2013).
Collectively, our studies highlight the miR-223–
NLRP3–IL-1β regulatory circuit as a critical component of 
intestinal inflammation. miR-223 serves to constrain the level 
of NLRP3 activation and provides an early break, limiting cy-
tokine-mediated immune disequilibrium. Thus, as miR-223 
can restrain pathological intestinal inflammation, genetic or 
pharmacologic stabilization of miR-223 may hold promise 
as a future novel therapeutic modality for active flares in IBD.
MAterIALs And MetHods
Human subjects
The institutional review board of the University of Colorado 
Denver approved all human studies. CD and UC patients 
were diagnosed using established criteria and CD phenotype 
per the Montreal criteria (Satsangi et al., 2006; see Table 1 
for patient characteristics). Patient demographics and medi-
cations were recorded at the time of endoscopic evaluation, 
during which mucosal biopsies were obtained. The determi-
nation of disease activity was based on endoscopic evidence 
of mucosal inflammation.
Mouse strains
miR-223-/y mice on a C57BL/6J background were provided 
by V. Dawson (Johns Hopkins University, Baltimore, MD) 
and bred in-house. CD45.1 (B6.SJL-PtprcaPep3b/BoyJ) were 
purchased from The Jackson Laboratory. C57BL/6J (CD45.2) 
mice were bred in-house. Experimental mice were housed 
separately according to genotype (i.e., B6.WT vs. miR-
223-/y), matched for age and sex, and typically 8–12 wk of age. 
In one series of studies (Fig. S1), WT and miR-223-/y mice 
were cohoused from weaning (21 d), and experimental colitis 
Table 1. clinical characteristics of study subjects
Phenotype n Age (mean) Disease duration (mean) Current IBD medications
Prednisone AZA/6MP Anti-TNF
yr yr
Healthy controls 10 51.4 NA 0% 0% 0%
Inactive UC 6 47.8 16.8 33% 50% 0%
Active UC 6 51.5 8.8 50% 33% 0%
Inactive Crohn's 4 47.5 22.0 0% 17% 33%
Active Crohn's 6 36.7 5.0 33% 0% 0%
NA, not applicable.
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was induced at 8 wk of age. All mice were bred under specific 
pathogen–free conditions, and fecal samples were negative 
for Helicobacter species, protozoa, and helminthes. Animal 
procedures were approved by the Institutional Animal Care 
and Use Committees at the University of Colorado Denver 
and the Walter and Eliza Hall Institute of Medical Research/
University of Melbourne.
Generation of the nlrp3m223del mouse
Mice lacking the miR-223 target site in the Nlrp3 3′ UTR 
were generated by Ingenious targeting laboratory (Ronkon-
koma, NY) on a C57BL/6 background. Two loxP sites were 
introduced flanking 100 bp in the Nlrp3 locus that contain 
the miR-223 target site, 5′-ATA ACT TCG TAT AGC ATA 
CAT TAT ACG AAG TTATCTG GGC CTC TGG TTT TTT 
GAC CTT TGC CCA TAC CTT CAGTCT TGT CTT CCT 
GTT AAC TGA CCATC CCG CAT AAG GAG CTG CCC 
GTG GGCATA ACT TCG TAT AGC ATA CAT TAT ACG 
AAG TTAT-3′ (loxP sites in italics and miR-223 target site 
underlined). In addition, a biotinylation reporter sequence 
(BirA) recognition site, 5′-ATG GCC AGC AGC CTC AGA 
CAG ATC CTC GAC AGC CAG AAG ATG GAG TGG AGA 
AGC AAC GCC GGC GGC AGC-3′ (coding for MAS SLR 
QIL DSQ KME WRS NAG GS), was added to the 3′ end of 
the Nlrp3 coding region. Transgenic mice were crossed with 
CMV-Cre mice (The Jackson Laboratory) to delete the 
miRNA target site. All animal experiments were performed 
under the standards of, and were approved by, the Walter and 
Eliza Hall Institute Animal Ethics Committee.
Generation of BM chimeric mice
Femurs and tibias from WT (CD45.1 or CD45.2) and miR-
223-/y (CD45.2) donor mice were removed and flushed 
through a 70-µm cell strainer with cold RPMI 1640 to har-
vest BM cells. Recipient mice (8–12 wks of age) were irradi-
ated with a total dose of 1,000 rads (500 rads twice, 4 h apart). 
Immediately after irradiation, 1 × 107 BM cells/mouse were 
intravenously injected via the retro-orbital route in 0.1 ml 
0.9% sodium chloride. Mice were housed in microisolator 
cages for 8 wks to recover before induction of DSS-colitis. 
To assess BM reconstitution, spleens were excised at necropsy, 
and red blood cells were lysed, followed by flow cytometry 
for CD45+ leukocytes expressing either CD45.1 (clone A20) 
or CD45.2 (clone 104; eBioscience).
Induction of experimental dss-colitis and treatment studies
DSS (3% wt/vol, 36,000–50,000 kD; MP Biomedicals) was 
administered in drinking water ad libitum for 6 d. DSS solu-
tion was replaced once on day 3. Examination for clinical 
signs of colitis (i.e., weight loss, stool consistency, and fecal 
blood) were performed and recorded daily. A colitis DAI was 
calculated for each mouse daily, based on body weight loss, 
occult blood, and stool consistency. A score of 1–4 was given 
for each parameter (0: no weight loss, normal stool, no blood; 
1: 1–3% weight loss; 2: 3–6% weight loss, loose stool, blood 
visible in stool; 3: 6–9% weight loss; 4: >9% weight loss, di-
arrhea, gross bleeding), with a maximum DAI score of 12. 
Loose stool was defined as the formation of a stool pellet that 
readily loses consistency upon handling. Diarrhea was defined 
as no pellet formation. Gross bleeding was defined as fresh 
perianal blood with obvious hematochezia. Upon necropsy, 
colon length was additionally measured.
To deplete neutrophils during DSS-colitis, miR-223-/y 
mice were treated i.p. with 300 µg anti-Ly6G (1A8) or iso-
type control daily from days 0–5. To deplete monocytes, miR-
223-/y mice were treated i.p. with 20 µg anti-CCR2 (MC21) 
or isotype control daily from days 0–5 after DSS. Mice were 
euthanized 24 h after the terminal treatment.
To inhibit the NLRP3 inflammasome in vivo, miR-
223-/y mice were treated i.p. with 20 mg/kg MCC950 (Coll 
et al., 2015) or saline vehicle daily on days 0–5 of DSS treat-
ment. To block IL-1β in vivo, miR-223-/y mice were treated 
i.p. with 20 mg/kg of anakinra or a saline vehicle daily on 
days 0–5 of DSS treatment. Mice were euthanized 24 h after 
the last treatment on day 6 after DSS.
tissue fixation, paraffin embedding, and histological scoring
Colons were excised, opened longitudinally, and washed with 
cold PBS followed by fixation with 10% buffered formalin. 
Tissue was embedded in paraffin, cut into 5-µm sections, and 
stained with hematoxylin and eosin (H&E). Histological as-
sessment of colitis was performed by a board-certified pathol-
ogist, who was blinded to experimental details, as previously 
described (McNamee et al., 2010).
Isolation, culture, and treatment of mouse BMdMs  
and neutrophils
Mouse BM from femurs and tibias was resuspended in HBSS-
EDTA, and BMDMs were isolated, cultured, and activated 
for 5 d as previously described (Mosser and Zhang, 2008). 
For NLRP3 inflammasome activation, 106 cells/ml BMDM 
were treated with LPS (100 ng/ml) for 3 h followed by ATP 
(1 mM; InvivoGen) for 3 h or vehicle controls. For neutrophil 
isolation, BM was resuspended in HBSS-EDTA and layered 
on a Percoll gradient (52, 69, and 78%) in 1× HBSS. Neu-
trophils were removed from the 69/72% interphase. Cells 
were washed twice with HBSS and seeded at 106 cells/ml in 
OptiMEM supplemented with 1 µg/ml aprotinin. NLRP3 
was activated by 3-h LPS priming (100 ng/ml) followed by 
3-h stimulation with 10 µM nigericin. After the combined 
treatments, cell-free supernatants were harvested, and cells 
were washed and harvested for either mRNA or protein 
extraction and analysis.
For functional studies assessing the role of miR-223 in 
the Nlrp3 binding site–deficient mice, primary monocytes 
were isolated using anti-CD14 magnetic beads from WT or 
nlrp3m223del BM (Miltenyi Biotec) and differentiated by incu-
bation with 100 ng/ml M-CSF for 3 d. Primary monocytes 
were transfected with 25 nM control scrambled or miR-223 
mimic using Dharmafect reagent 3 (Thermo Fisher Scien-
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tific) and activated with 1 µg/ml LPS and 5 mM ATP (Sig-
ma-Aldrich) as previously described (Haneklaus et al., 2012).
Leukocyte isolation and flow cytometry
Colons were excised, opened longitudinally, and washed with 
cold PBS followed by incubation with IEL solution (PBS, 
15 mmol/L Hepes, and 1 mmol/L EDTA) to remove epithe-
lial cells. Colons were cut into ∼1-cm pieces and then enzy-
matically digested (RPMI, 2% FCS, 15 mmol/L Hepes, 200 
U/ml collagenase VIII [Sigma-Aldrich], and 1 µg/ml DNase 
[Thermo Fisher Scientific]) at 37°C with gentle agitation for 
∼30 min. Debris was extracted using a 100-µM filter, and the 
cell suspension was washed with cold RPMI/10% FBS twice. 
Cells from indicated compartments were incubated with 
fluorescently labeled anti-mouse antibodies against MHC 
II (M5/114.15.2), CD11b (M1/70), CD11c (N418), Ly6G 
(1A8), Ly6C (HK1.4), CD45 (30-F11), CD115 (AFS98; 
eBioscience, San Diego, CA), or corresponding isotype con-
trols. Dead cells were excluded using a Live/Dead Fixable 
Aqua Stain (Invitrogen), and flow cytometry was performed 
using a BD FAC SCanto II (BD). Further analyses were per-
formed using FLO WJo software (Tree Star).
mirnA and mrnA transcriptional analysis
Total RNA or separated fractions of miRNA and mRNA 
were isolated from colon tissue using Qiazol Reagent and 
an RNeasy kit according to the manufacturer’s instructions 
(Qiagen). Transcript levels were determined by real-time RT-
PCR using specific primer sets (miRNA, Qiagen; mRNA, 
Taqman, Applied Biosystems). Expression levels of miRNAs 
were normalized to endogenous RNU-6, whereas 18s was 
used to normalize mRNA expression profiles.
Western immunoblot analysis of nLrP3, IL-1β, and Asc
To measure NLRP3, ASC and IL-1β protein content, pel-
leted BMDMs, neutrophils, or colon biopsies were freeze-
thawed in T-Per Tissue Protein Extraction Reagent with 
Pierce Phosphatase and Protease Inhibitor (Thermo Fisher 
Scientific). Supernatant protein concentration was quantified 
using Pierce BCA Protein Assay kit (Thermo Fisher Scien-
tific), resuspended in reducing 4× Laemmli sample buffer 
(Bio-Rad) and heated to 98°C for 10 min. Samples were re-
solved on a 10% polyacrylamide gel and semi-dry transferred 
to nitrocellulose membranes. The membranes were blocked 
for 30 min at room temperature in TBS-T supplemented 
with 5% blotting-grade nonfat milk (Bio-Rad). Membranes 
were subsequently incubated with rabbit anti-mouse NLRP3 
(D4D8T; Cell Signaling Technology) at a concentration of 
1:150, rabbit anti-mouse ASC (N-15; Santa Cruz Biotech-
nology, Inc.) at a concentration of 1:500, or goat anti-mouse 
IL-1β (AF-401-NA; R&D Systems) at a concentration of 
1:200 overnight at 4°C. After three 15-min washes in TBS-T, 
NLRP3, ASC, and IL-1β membranes were incubated in goat 
anti–rabbit IgG-HRP secondary Ab (Santa Cruz Biotech) or 
bovine anti–goat IgG-HRP secondary Ab (Santa Cruz Bio-
technology, Inc.) at concentrations of 1:2,000 to 1:5,000 for 
2 h at room temperature. Membranes were washed in TBS-T, 
and proteins were detected by enhanced chemiluminescence 
(Thermo Fisher Scientific). To control for protein loading, 
blots were stripped and reprobed for β-actin (I-19; Santa 
Cruz Biotechnology, Inc.) and a bovine anti–goat IgG-HRP 
secondary Ab (Santa Cruz Biotechnology, Inc.).
cytokine analysis from intestinal tissues and 
cell culture supernatant
Cytokine analysis was performed on colon intestinal tissue or 
cell culture supernatants using mouse IL-18 Platinum ELI SA 
kits (eBioscience), Duoset mouse IL-1β and TNF ELI SA 
kits (R&D Systems), and LEG ENDplex Mouse Inflamma-
tion panel (13-plex; BioLegend) according to the manu-
facturers’ instructions.
In vivo nanoparticle delivery of mmu-mir-223 mimetic
To use a pharmacological approach to overexpress mmu-
miR-223 during experimental DSS-colitis, a nanopar-
ticle-based approach was used to transport synthetic 
mmu-miR-223. NLE consists of 1,2-dioleoyl-sn-glycero- 
3-phosphocholine, squalene oil, polysorbate 20, and an an-
tioxidant that, in complex with synthetic miRNAs, form 
nanoparticles in the nanometer diameter range. Mice were 
treated i.v., via retro-orbital route (days 1 and 3 after DSS) 
with a dose of 50 µg synthetic mmu-miR-223 (mimic-223; 
Dharmacon) or respective control (Cel-miR-239b) formu-
lated with NLE according to the manufacturer’s instructions 
(MaxSuppressor In Vivo RNA-LAN CEr II; Bioo Scientific).
statistical analysis
Statistical analyses were performed using ANO VA or two-
tailed Student’s t test. Data were expressed as mean ± SEM. 
Statistical significance was set at P < 0.05.
online supplemental material
Fig. S1 shows clinical and histopathology data for a DSS-coli-
tis study using either single or cohoused WT and miR-223-/y 
mice. Fig. S2 shows a schematic representation for the devel-
opment of the nlrp3m223del mouse. Fig. S3 demonstrates that 
BMDM from nlrp3m223del mice are refractory to repression of 
Nlrp3 with miR-223 mimetics.
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